Literature DB >> 17720497

Myasthenia gravis in South Africans: racial differences in clinical manifestations.

J M Heckmann1, E P Owen, F Little.   

Abstract

We present data on the phenotypic variation in myasthenia gravis of 205 subjects from a multi-racial South African cohort. Consecutive subjects seen more than twice from 1996 to 2006, were included. Documented observational data included a myasthenia gravis and extra-ocular eye muscle score. Results showed Black subjects were more likely than Whites to develop treatment-resistant complete ophthalmoplegia and ptosis (18% vs. 2%; p=0.041). Of the 14 patients with this phenotype, 13 had generalised disease and positive AChR antibodies. Despite similar sized cohorts, White subjects were more likely than Blacks to develop generalised myasthenia poorly responsive to therapy (p=0.005). There were no significant racial differences in the time between diagnosis to initiation of therapy, or the performance and timing of thymectomy. The racial variation in some phenotypic features of myasthenia gravis and outcome to therapy, highlights the need to study biological factors in different subgroups to develop a more rational approach to immuno-suppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720497     DOI: 10.1016/j.nmd.2007.07.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  14 in total

1.  [Clinical and paraclinical profile of autoimmune myasthenia gravis in Ouagadougou, Burkina Faso].

Authors:  Djingri Labodi Lompo; Nagaonlé Éric Some; Adja Mariam Ouedraogo; Rodrigue P Yonli; Ousséini Diallo; Christian Napon; Athanase Millogo; Jean Kabore
Journal:  Med Trop Sante Int       Date:  2021-11-11

2.  Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases.

Authors:  Tarin A Europa; Melissa Nel; Maribanyana R Lebeko; Jeannine M Heckmann
Journal:  IBRO Neurosci Rep       Date:  2022-04-21

3.  The MGTX experience: challenges in planning and executing an international, multicenter clinical trial.

Authors:  Inmaculada B Aban; Gil I Wolfe; Gary R Cutter; Henry J Kaminski; Alfred Jaretzki; Greg Minisman; Robin Conwit; John Newsom-Davis
Journal:  J Neuroimmunol       Date:  2008-09-15       Impact factor: 3.478

4.  Racial differences in myasthenia gravis in Alabama.

Authors:  Shin J Oh; Marla B Morgan; Liang Lu; Yuki Hatanaka; Shoji Hemmi; Angela Young; Gwendolyn C Claussen
Journal:  Muscle Nerve       Date:  2009-03       Impact factor: 3.217

5.  The African-387 C>T TGFB1 variant is functional and associates with the ophthalmoplegic complication in juvenile myasthenia gravis.

Authors:  Melissa Nel; Joy-Mari Buys; Robyn Rautenbach; Shaheen Mowla; Sharon Prince; Jeannine M Heckmann
Journal:  J Hum Genet       Date:  2015-12-03       Impact factor: 3.172

6.  A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.

Authors:  Jeannine M Heckmann; Amanullah Rawoot; Kathleen Bateman; Rudi Renison; Motasim Badri
Journal:  BMC Neurol       Date:  2011-08-05       Impact factor: 2.474

7.  Exome sequencing identifies novel dysferlin mutation in a family with pauci-symptomatic heterozygous carriers.

Authors:  Mahjoubeh Jalali-Sefid-Dashti; Melissa Nel; Jeannine M Heckmann; Junaid Gamieldien
Journal:  BMC Med Genet       Date:  2018-06-07       Impact factor: 2.103

Review 8.  The epidemiology of myasthenia gravis.

Authors:  Ana-Maria Bubuioc; Aigerim Kudebayeva; Saule Turuspekova; Vitalie Lisnic; Maurizio Angelo Leone
Journal:  J Med Life       Date:  2021 Jan-Mar

9.  A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.

Authors:  J M Heckmann; H Uwimpuhwe; R Ballo; M Kaur; V B Bajic; S Prince
Journal:  Genes Immun       Date:  2009-08-13       Impact factor: 2.676

10.  Myasthenia gravis: presentation and outcome in 104 patients managed in a single institution.

Authors:  Mansour A Al-Moallem; Nura H Alkali; Mohammed A Hakami; Radwan M Zaidan
Journal:  Ann Saudi Med       Date:  2008 Sep-Oct       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.